GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
GT Biopharma (NASDAQ: GTBP) announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024, in New York, NY. Dr. Jeffrey Miller, GT Biopharma's Consulting Senior Medical Director, will join a panel discussion on innovative therapies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
The panel, titled 'Focus: Hematologic malignancies', is scheduled for 1:15-1:55 pm ET. Dr. Miller, who is also the Deputy Director of the Masonic Cancer Center and Co-Leader of the Immunology Program at the University of Minnesota Medical School, will share insights on GT Biopharma's NK cell engager TriKE® platform.
Company management will be available for one-on-one meetings during the event. Interested parties can arrange meetings through their ROTH representatives.
GT Biopharma (NASDAQ: GTBP) ha annunciato la sua partecipazione alla 3ª Conferenza Annuale ROTH sulle Opportunità Sanitarie il 9 ottobre 2024 a New York, NY. Il Dr. Jeffrey Miller, Direttore Medico Senior Consultivo di GT Biopharma, parteciperà a una tavola rotonda sulle terapie innovative per la leucemia mieloide acuta (LMA) e il syndrome mielodisplastica (MDS).
Il pannello, intitolato 'Focus: Malignità ematologiche', è previsto dalle 13:15 alle 13:55 ET. Il Dr. Miller, che è anche Vice Direttore del Masonic Cancer Center e Co-Leader del Programma di Immunologia presso la Facoltà di Medicina dell'Università del Minnesota, condividerà informazioni sulla piattaforma NK cell engager TriKE® di GT Biopharma.
La direzione dell'azienda sarà disponibile per incontri individuali durante l'evento. Le parti interessate possono organizzare incontri tramite i loro rappresentanti ROTH.
GT Biopharma (NASDAQ: GTBP) anunció su participación en la 3ª Conferencia Anual de Oportunidades de Salud ROTH el 9 de octubre de 2024 en Nueva York, NY. El Dr. Jeffrey Miller, Director Médico Senior Consultivo de GT Biopharma, se unirá a una discusión en panel sobre terapias innovadoras para la leucemia mieloide aguda (LMA) y el síndrome mielodisplásico (MDS).
El panel, titulado 'Enfoque: Malignidades Hematológicas', está programado para las 1:15-1:55 PM ET. El Dr. Miller, quien también es el Director Adjunto del Masonic Cancer Center y Co-Líder del Programa de Inmunología en la Facultad de Medicina de la Universidad de Minnesota, compartirá conocimientos sobre la plataforma NK cell engager TriKE® de GT Biopharma.
La dirección de la empresa estará disponible para reuniones individuales durante el evento. Las partes interesadas pueden organizar reuniones a través de sus representantes de ROTH.
GT Biopharma (NASDAQ: GTBP)는 2024년 10월 9일 뉴욕(NY)에서 열리는 제3회 연례 ROTH 헬스케어 기회 회의에 참석한다고 발표했습니다. 제프리 밀러 박사, GT Biopharma의 고문 의료 이사는 급성 골수성 백혈병(AML)과 골수 이형성 증후군(MDS)을 위한 혁신적인 치료법에 대한 패널 토론에 참여할 예정입니다.
'혈액 악성종양 집중'이라는 제목의 패널은 오후 1시 15분부터 1시 55분(동부 표준시)까지 예정되어 있습니다. 밀러 박사는 미네소타 대학교 의과대학의 메이슨 암센터 부소장 및 면역학 프로그램 공동 리더로 재직 중이며, GT Biopharma의 NK 세포 연결제 TriKE® 플랫폼에 대한 통찰력을 공유할 것입니다.
회사의 경영진은 행사 동안 1:1 미팅을 위해 대기할 것입니다. 관심 있는 당사자는 ROTH 대표를 통해 미팅을 조율할 수 있습니다.
GT Biopharma (NASDAQ: GTBP) a annoncé sa participation à la 3e Conférence Annuelle ROTH sur les Opportunités de Santé le 9 octobre 2024 à New York, NY. Le Dr Jeffrey Miller, Directeur Médical Senior Consultant de GT Biopharma, participera à une discussion en panel sur les thérapies innovantes pour la leucémie myéloïde aiguë (LMA) et le syndrome myélodysplasique (SMD).
Le panel, intitulé 'Focus : Malignités hématologiques', est prévu de 13h15 à 13h55 ET. Le Dr Miller, qui est également le Directeur Adjoint du Masonic Cancer Center et Co-Leader du Programme d'Immunologie à l'École de Médecine de l'Université du Minnesota, partagera des informations sur la plateforme NK cell engager TriKE® de GT Biopharma.
La direction de l'entreprise sera disponible pour des réunions individuelles pendant l'événement. Les parties intéressées peuvent organiser des réunions par l'intermédiaire de leurs représentants ROTH.
GT Biopharma (NASDAQ: GTBP) gab seine Teilnahme an der 3. Jahreskonferenz für Gesundheitschancen von ROTH am 9. Oktober 2024 in New York, NY, bekannt. Dr. Jeffrey Miller, der Senior Medical Director Consult von GT Biopharma, wird an einer Podiumsdiskussion über innovative Therapien für akute myeloische Leukämie (AML) und myelodysplastisches Syndrom (MDS) teilnehmen.
Das Panel mit dem Titel 'Fokus: Hämatologische Malignome' ist von 13:15 bis 13:55 Uhr ET geplant. Dr. Miller, der auch stellvertretender Direktor des Masonic Cancer Center und Co-Leiter des Immunologieprogramms an der University of Minnesota Medical School ist, wird Einblicke in die NK-Zellen-Engager TriKE® Plattform von GT Biopharma geben.
Das Unternehmensmanagement wird während der Veranstaltung für Eins-zu-eins-Meetings zur Verfügung stehen. Interessierte Parteien können über ihre ROTH-Vertreter Meetings vereinbaren.
- None.
- None.
SAN FRANCISCO, CALIFORNIA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced that Dr. Jeffrey Miller, MD1, from the University of Minnesota Medical School2 and GT Biopharma’s Consulting Senior Medical Director, will participate in a panel discussion on innovative therapies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) at the 3rd Annual ROTH Healthcare Opportunities Conference taking place October 9, 2024 in New York, NY. Company management will also be participating in 1x1 meetings during the event.
| 3rd Annual ROTH Healthcare Opportunities Conference – October 9, 2024 | |
| Title: | Panel 4 – Focus: Hematologic malignancies |
| Date: | Wednesday, October 9, 2024 |
| Time: | 1:15-1:55 pm ET |
| Participant: | Dr. Jeffrey Miller, MD, Deputy Director, Masonic Cancer Center, Co-Leader Immunology Program at the University of Minnesota Medical School & Consulting Senior Medical Director, GT Biopharma |
If you are interested in arranging a 1x1 meeting request with management, please contact your ROTH representative.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell engager platform. Our TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology. For more information, please visit gtbiopharma.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.
TriKE® is a registered trademark owned by GT Biopharma, Inc.
Investor Relations Contact:
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577
1 Dr. Miller is the Consulting Senior Medical Director at GT Biopharma and holds stock and options in GTBP.
2 The University of Minnesota, pursuant to its license agreement with GT Biopharma, is entitled to receive royalties should commercial sales of GTB-3650 be realized. This interest has been reviewed and managed by the University of Minnesota in accordance with its conflict of interest policies.
FAQ
When and where is GT Biopharma (GTBP) participating in the ROTH Healthcare Opportunities Conference?
Who will represent GT Biopharma (GTBP) at the ROTH Healthcare Opportunities Conference panel?
What topics will be discussed in GT Biopharma's (GTBP) panel at the ROTH conference?
What is the time and title of GT Biopharma's (GTBP) panel at the ROTH conference?
How can investors arrange meetings with GT Biopharma (GTBP) management at the ROTH conference?
